Leonard Y Chu1, Ling Ye2, Ke Dong2, Richard W Compans2, Chinglai Yang2, Mark R Prausnitz3,4. 1. Wallace H. Coulter Department of Biomedical Engineering, Georgia Technology and Emory University, Georgia Institute of Technology, Atlanta, Georgia, 30332, USA. 2. Department of Microbiology and Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, 30329, USA. 3. Wallace H. Coulter Department of Biomedical Engineering, Georgia Technology and Emory University, Georgia Institute of Technology, Atlanta, Georgia, 30332, USA. prausnitz@gatech.edu. 4. School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, 311 Ferst Drive, Atlanta, Georgia, 30332, USA. prausnitz@gatech.edu.
Abstract
PURPOSE: This study tested the hypothesis that encapsulation of influenza vaccine in microneedle patches increases vaccine stability during storage at elevated temperature. METHODS: Whole inactivated influenza virus vaccine (A/Puerto Rico/8/34) was formulated into dissolving microneedle patches and vaccine stability was evaluated by in vitro and in vivo assays of antigenicity and immunogenicity after storage for up to 3 months at 4, 25, 37 and 45°C. RESULTS: While liquid vaccine completely lost potency as determined by hemagglutination (HA) activity within 1-2 weeks outside of refrigeration, vaccine in microneedle patches lost 40-50% HA activity during or shortly after fabrication, but then had no significant additional loss of activity over 3 months of storage, independent of temperature. This level of stability required reduced humidity by packaging with desiccant, but was not affected by presence of oxygen. This finding was consistent with additional stability assays, including antigenicity of the vaccine measured by ELISA, virus particle morphological structure captured by transmission electron microscopy and protective immune responses by immunization of mice in vivo. CONCLUSIONS: These data show that inactivated influenza vaccine encapsulated in dissolving microneedle patches has enhanced stability during extended storage at elevated temperatures.
PURPOSE: This study tested the hypothesis that encapsulation of influenza vaccine in microneedle patches increases vaccine stability during storage at elevated temperature. METHODS: Whole inactivated influenza virus vaccine (A/Puerto Rico/8/34) was formulated into dissolving microneedle patches and vaccine stability was evaluated by in vitro and in vivo assays of antigenicity and immunogenicity after storage for up to 3 months at 4, 25, 37 and 45°C. RESULTS: While liquid vaccine completely lost potency as determined by hemagglutination (HA) activity within 1-2 weeks outside of refrigeration, vaccine in microneedle patches lost 40-50% HA activity during or shortly after fabrication, but then had no significant additional loss of activity over 3 months of storage, independent of temperature. This level of stability required reduced humidity by packaging with desiccant, but was not affected by presence of oxygen. This finding was consistent with additional stability assays, including antigenicity of the vaccine measured by ELISA, virus particle morphological structure captured by transmission electron microscopy and protective immune responses by immunization of mice in vivo. CONCLUSIONS: These data show that inactivated influenza vaccine encapsulated in dissolving microneedle patches has enhanced stability during extended storage at elevated temperatures.
Authors: Hyo-Jick Choi; Dae-Goon Yoo; Brian J Bondy; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz Journal: Biomaterials Date: 2012-02-21 Impact factor: 12.479
Authors: Dimitrios G Koutsonanos; Maria del Pilar Martin; Vladimir G Zarnitsyn; Joshy Jacob; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou Journal: J Infect Dis Date: 2011-06-17 Impact factor: 5.226
Authors: Jae-Min Song; Yeu-Chun Kim; Aleksandr S Lipatov; Marc Pearton; C Todd Davis; Dae-Goon Yoo; Kyoung-Mi Park; Li-Mei Chen; Fu-Shi Quan; James C Birchall; Ruben O Donis; Mark R Prausnitz; Richard W Compans; Sang-Moo Kang Journal: Clin Vaccine Immunol Date: 2010-07-14
Authors: Marc Pearton; Daniela Pirri; Sang-Moo Kang; Richard W Compans; James C Birchall Journal: Adv Healthc Mater Date: 2013-04-08 Impact factor: 9.933
Authors: James J Norman; Jaya M Arya; Maxine A McClain; Paula M Frew; Martin I Meltzer; Mark R Prausnitz Journal: Vaccine Date: 2014-02-11 Impact factor: 3.641
Authors: Rong Yang; Tuo Wei; Hannah Goldberg; Weiping Wang; Kathleen Cullion; Daniel S Kohane Journal: Adv Mater Date: 2017-07-28 Impact factor: 30.849
Authors: Stephen C Balmert; Cara Donahue Carey; Gabriel D Falo; Shiv K Sethi; Geza Erdos; Emrullah Korkmaz; Louis D Falo Journal: J Control Release Date: 2019-11-19 Impact factor: 9.776
Authors: Ying Liu; Ling Ye; Fang Lin; Yasmine Gomaa; David Flyer; Ricardo Carrion; Jean L Patterson; Mark R Prausnitz; Gale Smith; Gregory Glenn; Hua Wu; Richard W Compans; Chinglai Yang Journal: J Infect Dis Date: 2018-11-22 Impact factor: 5.226
Authors: Vincent Leung; Jonathan Mapletoft; Ali Zhang; Amanda Lee; Fatemeh Vahedi; Marianne Chew; Alexandra Szewczyk; Sana Jahanshahi-Anbuhi; Jann Ang; Braeden Cowbrough; Matthew S Miller; Ali Ashkar; Carlos D M Filipe Journal: Sci Rep Date: 2019-05-21 Impact factor: 4.379
Authors: Ying Liu; Ling Ye; Fang Lin; Yasmine Gomaa; David Flyer; Ricardo Carrion; Jean L Patterson; Mark R Prausnitz; Gale Smith; Gregory Glenn; Hua Wu; Richard W Compans; Chinglai Yang Journal: Sci Rep Date: 2018-07-25 Impact factor: 4.379